Ionis attributed the rise in revenue to “significant partner payments,” including $51 million in milestone payments and $20 million in license fees.
Rebates and discounts paid to healthcare middlemen again lowered — or slowed growth in — big drugmakers’ selling prices.
The R&D investment made by the nearly dozen largest drug manufacturers totaled $104 billion last year.
Moderna and IBM struck a deal to provide the vaccine maker with generative artificial intelligence that will help it develop mRNA therapies.
Advocates for pharmacy benefit managers launched a seven-figure ad blitz, as Congress looks set for a wave of PBM hearings and potential legislation.
As a new research paper spurs debate, the countdown is ticking on a pandemic-era policy change that may affect the controversial marketing tactic.
Is the healthcare industry’s compassion misplaced? Russians aren’t waiting to find out.
The drugmaker is setting aside the typical rep-driven model for the U.S. launch of Leqvio (inclisiran). But can it avoid access pitfalls?
On tap are 14 novel therapies to replace revenue lost from the separation of its consumer unit as well as the patent cliff on aging drugs.
MM+M is proud to announce the fourth annual Pinnacle Awards program, which celebrates the medical marketing industry’s most venerable marketers, strategists and creators.
Get the most out of
Register for free and enjoy unlimited access to:
